On August 16, 2017 Medigene AG (FSE: MDG1, Prime Standard, TecDAX) reported that scientists of the Company were invited to present two posters on its T cell receptor (TCR)-modified T cell therapies during the upcoming CRI-CIMT-EATI-AACR Conference (Press release, MediGene, AUG 16, 2017, View Source [SID1234520275]). The Cancer Research Institute (CRI), the Association for Cancer lmmunotherapy (CIMT) (Free CIMT Whitepaper), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) (Free AACR Whitepaper) sponsor the Third International Cancer lmmunotherapy Conference that takes place in Mainz, Germany, from September 6-9, 2017.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the "Neoantigens and Cancer Mutations" session, Dr. Christiane Mummert, scientist at Medigene Immunotherapies, will present her poster describing a semi-automated method for the isolation and initial characterization of neoantigen-specific T cell receptors. In summary, the experiments demonstrated that neoantigen-specific TCRs can be isolated from peripheral blood samples of healthy donors and initially characterized in eight to ten weeks using an innovative high-throughput robotics platform.

On the second poster, presented during the "Adoptive Cell Therapy" session, shared co-authors Dr. Christian Ellinger and Dr. Manon Weis describe properties of Medigene’s PRAME-specific TCR for adoptive T cell immunotherapy of cancer. Using an innovative TCR isolation and characterization platform, a TCR with natural high avidity for a PRAME-derived epitope was isolated showing potent efficacy and a favorable safety profile that will be further evaluated in clinical trials.

Both posters will be presented during "Poster Session A" that will take place on September 6 between 6:00 pm – 8:00 pm.

About Medigene’s TCR technology: The TCR technology aims at arming the patient’s own T cells with tumor-specific T cell receptors (TCRs). The receptor-modified T cells are then able to detect and efficiently kill tumor cells. This immunotherapy approach attempts to overcome the patient’s tolerance towards cancer cells and tumor-induced immunosuppression by activating and modifying the patient’s T cells outside the body (ex vivo).
TCR therapy is developed to utilize a higher number of potential tumor antigens than other T cell-based immunotherapies, such as chimeric antigen receptor T cell (CAR T) therapy. Medigene is preparing the clinical development of its first TCR candidates and is establishing a pipeline of recombinant T cell receptors, and has established Good Manufacturing Practice (GMP)-compliant processes for their combination with patient-derived T cells.

Medigene’s first TCR immunotherapy "MDG1011" will be tested in a clinical Phase I/II trial intended to be started by the end of 2017.

Besides the planned company-sponsored TCR trial, Medigene is involved in an investigator-initiated trial (IIT) with TCRs in multiple myeloma (MM) to be conducted by the Charité – Universitätsmedizin Berlin in cooperation with the Max Delbrück Centre (MDC), Berlin.